ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander Sells 5,555 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander sold 5,555 shares of the business’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $135.55, for a total value of $752,980.25. Following the completion of the transaction, the chief operating officer now directly owns 2,389 shares in the company, valued at approximately $323,828.95. This represents a 69.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

ICU Medical Trading Up 3.4%

Shares of ICUI opened at $140.54 on Friday. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $100.91 and a 12-month high of $196.26. The firm has a market capitalization of $3.46 billion, a PE ratio of -30.75 and a beta of 0.87. The stock’s fifty day simple moving average is $140.80 and its 200-day simple moving average is $154.33.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.49. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The firm had revenue of $599.49 million during the quarter, compared to analysts’ expectations of $574.15 million. During the same period in the previous year, the business posted $0.96 EPS. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. As a group, research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Institutional Investors Weigh In On ICU Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in ICU Medical by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock worth $416,176,000 after acquiring an additional 17,805 shares during the period. JPMorgan Chase & Co. boosted its position in shares of ICU Medical by 7.4% in the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock worth $109,920,000 after purchasing an additional 49,108 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of ICU Medical by 18.5% in the 1st quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier’s stock worth $96,326,000 after purchasing an additional 108,493 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ICU Medical by 18.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock worth $83,788,000 after purchasing an additional 82,982 shares during the period. Finally, Northern Trust Corp increased its holdings in ICU Medical by 11.1% in the fourth quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier’s stock valued at $62,431,000 after purchasing an additional 40,187 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ICUI shares. KeyCorp lowered their target price on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. StockNews.com cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. Raymond James dropped their target price on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and an average target price of $192.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.